Article

Antibacterial activity of antileukoprotease.

Department of Pulmonology, Leiden University Hospital, The Netherlands.
Infection and Immunity (Impact Factor: 4.16). 12/1996; 64(11):4520-4.
Source: PubMed

ABSTRACT Antileukoprotease (ALP), or secretory leukocyte proteinase inhibitor, is an endogenous inhibitor of serine proteinases that is present in various external secretions. ALP, one of the major inhibitors of serine proteinases present in the human lung, is a potent reversible inhibitor of elastase and, to a lesser extent, of cathepsin G. In equine neutrophils, an antimicrobial polypeptide that has some of the characteristics of ALP has been identified (M. A. Couto, S. S. L. Harwig, J. S. Cullor, J. P. Hughes, and R. I. Lehrer, Infect. Immun. 60:5042-5047, 1992). This report, together with the cationic nature of ALP, led us to investigate the antimicrobial activity of ALP. ALP was shown to display marked in vitro antibacterial activity against Escherichia coli and Staphylococcus aureus. On a molar basis, the activity of ALP was lower than that of two other cationic antimicrobial polypeptides, lysozyme and defensin. ALP comprises two homologous domains: its proteinase-inhibitory activities are known to be located in the second COOH-terminal domain, and the function of its first NH2-terminal domain is largely unknown. Incubation of intact ALP or its isolated first domain with E. coli or S. aureus resulted in killing of these bacteria, whereas its second domain displayed very little antibacterial activity. Together these data suggest a putative antimicrobial role for the first domain of ALP and indicate that its antimicrobial activity may equip ALP to contribute to host defense against infection.

0 Followers
 · 
101 Views
  • Source
    • "Examples include dermcidin and histone H4, which are expressed in eccrine sweat glands and by sebocytes, respectively, and secreted to the skin (Rieg et al., 2004; Lee et al., 2009). Moreover, secretory leukocyte protease inhibitor (SLPI) and elafin/elastase-specific inhibitor (ESI)/skin-derived antileukoprotease (SKALP) kill S. aureus (Hiemstra et al., 1996; Simpson et al., 1999), and the proteins can be induced in keratinocytes/epidermis (Bando et al., 2007). Another class of putative relevant antimicrobial proteins is the peptidoglycan recognition proteins (PGRPs; Dziarski and Gupta, 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Staphylococcus aureus may cause serious skin and soft tissue infections, deep abscesses, endocarditis, osteomyelitis, pneumonia, and sepsis. S. aureus persistently colonizes 25-30% of the adult human population, and S. aureus carriers have an increased risk for infections caused by the bacterium. The major site of colonization is the nose, i.e., the vestibulum nasi, which is covered with ordinary skin and hair follicles. Several host and microbe determinants are assumed to be associated with colonization. These include the presence and expression level of bacterial adhesins, which can adhere to various proteins in the extracellular matrix or on the cellular surface of human skin. The host expresses several antimicrobial peptides and lipids. The level of β-defensin 3, free sphingosine, and cis-6-hexadecenoic acid are found to be associated with nasal carriage of S. aureus. Other host factors are certain polymorphisms in Toll-like receptor 2, mannose-binding lectin, C-reactive protein, glucocorticoid-, and vitamin D receptor. Additional putative determinants for carriage include genetic variation and expression of microbial surface components recognizing adhesive matrix molecules and their interaction partners, as well as variation among humans in the ability of recognizing and responding appropriately to the bacteria. Moreover, the available microflora may influence the success of S. aureus colonization. In conclusion, colonization is a complex interplay between the bacteria and its host. Several bacterial and host factors are involved, and an increased molecular understanding of these are needed.
    Frontiers in Cellular and Infection Microbiology 05/2012; 2:56. DOI:10.3389/fcimb.2012.00056 · 2.62 Impact Factor
  • Source
    • "The domain structure of SLPI is similar to WFDC2 and earlier studies have shown SPLI has antibacterial activity localized to the amino terminal end 4-DSC domain while the carboxyl terminal end 4-DSC domain was found to contain no antibacterial activity (Hiemstra et al., 1996). The timing of elevated expression of the WFDC2 gene during pregnancy, early lactation (phase 2A) and during involution correlates with stages of the lactation cycle that have increased risk of infection (Basden et al., 1997; Daly et al., 2007; Old and Deane, 2000). "
    [Show abstract] [Hide abstract]
    ABSTRACT: WAP four disulfide core domain 2 (WFDC2) is a four disulfide core (4-DSC) protein secreted in the milk of the tammar wallaby. It is comprised of two 4-DSC domains assigned domain III at the NH2-terminal end and domain II at the COOH-terminal end. The WFDC2 gene was expressed only during pregnancy, early lactation, towards the end of lactation and involution. The WFDC2 protein showed antibacterial activity against Staphylococcus aureus, Salmonella enterica and Pseudomonas aeruginosa and this activity resided with domain II. There was no antibacterial activity detected against Enterococcus faecalis. The observed expression pattern of tammar WFDC2 and its antibacterial activity suggests a role to either reduce mastitis in the mammary gland caused by S. aureus or to protect the gut of the young at a time when it is not immune-competent. The latter effect could be achieved without disturbing the balance of commensal gut flora such as E. faecalis.
    Developmental and comparative immunology 03/2012; 36(3):584-90. DOI:10.1016/j.dci.2011.10.001 · 3.71 Impact Factor
  • Source
    • "[4] "
    Journal of dermatological science 05/2011; 63(2):128-31. DOI:10.1016/j.jdermsci.2011.04.014 · 3.34 Impact Factor
Show more

Preview

Download
0 Downloads
Available from